English
|
Spanish
Login
Register
For the latest
e
cancer COVID-19 resources, click on this link
Home
News
Journal
Video
e
learning
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
Conferences
Sign up for latest coverage
Submit your event
Conferences
e
cancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Past
Upcoming
Category
All
Disease Areas
Patient Care
Policy
Prevention & screening
Treatments
Sub-category
All
Region
All
Asia
Middle East and North Africa
Europe
North America
Central America and the Caribbean
South America
Africa
Australia and Oceania
Country
All
Year
All
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Keyword
ASCO 2020
27 May - 1 Jun 2020
Chicago, United States of America
Videos
News
PARP inhibitors and prostate cancer: A new era of precision medicine
Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain
4 Aug 2020
Oncology pharmacist perspective on PARP inhibitors for castration-resistant pros...
Dr Grace Martin - The University of Kansas Cancer Center, Kansas City, USA
27 Jul 2020
The role of PARP-2 in inhibiting prostate cancer
Prof Li Jia - Harvard Medical School, Boston, USA
27 Jul 2020
Lung cancer updates from ASCO 2020
Dr Luis Raez - Memorial Cancer Institute, Florida, USA
17 Jul 2020
KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advan...
Prof Scott Tykodi - University of Washington, Seattle, USA
14 Jul 2020
Association of gene expression with clinical outcomes in RCC patients treated wi...
Prof Scott Tykodi - University of Washington, Seattle, USA
14 Jul 2020
Renal cell cancer: Highlights from ASCO 2020
Prof Scott Tykodi - University of Washington, Seattle, USA
13 Jul 2020
FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-re...
Prof Scott Tykodi - University of Washington, Seattle, USA
13 Jul 2020
HERO: Relugolix versus leuprolide acetate for advanced prostate cancer
Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA
10 Jul 2020
The future of PARP inhibitors in prostate cancer
Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain
2 Jul 2020
COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected st...
Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
30 Jun 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
30 Jun 2020
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer
Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany
24 Jun 2020
MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemot...
Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal
18 Jun 2020
Early safety from a trial of talimogene laherparepvec (T-VEC) injected into live...
Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica, US...
17 Jun 2020
CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
17 Jun 2020
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA
16 Jun 2020
Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin l...
Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada
16 Jun 2020
FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2...
Prof Robert Huddart and Dr Ignacio Durán
15 Jun 2020
Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for re...
Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA
15 Jun 2020
High-dose twice daily thoracic radiotherapy in limited disease small-cell lung c...
Prof Bjørn Henning Grønberg - Trondheim University Hospital, Trondheim, Norway
15 Jun 2020
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for ...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
15 Jun 2020
Background of the KEYLYNK-007 trial for advanced solid tumours
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
13 Jun 2020
CTC count as a prognostic marker for androgen deprivation plus orteronel or bica...
Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA
12 Jun 2020
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in...
Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France
12 Jun 2020
AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurre...
Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany
12 Jun 2020
Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based thera...
Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy
12 Jun 2020
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma
Dr Katie Kelley - University of California San Francisco, San Francisco, USA
12 Jun 2020
Reducing damage to swallowing muscles during radiotherapy for head and neck canc...
Prof Christopher Nutting - The Royal Marsden NHS Foundation Trust, London, UK
12 Jun 2020
Updated results from KEYNOTE-426 for metastatic kidney cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
12 Jun 2020
HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve p...
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
12 Jun 2020
Comment: JAVELIN-100 for metastatic urothelial cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
12 Jun 2020
3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and n...
Dr Naomi Kiyota - Kobe University, Kobe, Japan
12 Jun 2020
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung can...
Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA
12 Jun 2020
METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer
Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA
12 Jun 2020
PARP inhibitors in prostate cancer: Choices of tests and how to test?
Dr Kim Chi and Dr Alexander Wyatt
11 Jun 2020
ASCO 2020: Breast cancer roundup
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
11 Jun 2020
FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple mye...
Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy
11 Jun 2020
The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients wi...
Dr Sara Lonardi - Istituto Oncologico Veneto, Padua, Italy
11 Jun 2020
Comparing pevonedistat plus azacitidine versus azacitidine alone in patients wit...
Prof Lionel Ades - Hôpital Saint-Louis, Paris, France
11 Jun 2020
ASCO 2020 prostate cancer highlights
Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl
10 Jun 2020
Perioperative novel systemic immunotherapy-based approaches in urinary cancers
Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA
9 Jun 2020
ASCO 2020: Updates in renal cancer
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
5 Jun 2020
TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochem...
Prof Benoit You - Hospices Civils de Lyon, Lyon, France
5 Jun 2020
KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/d...
Prof Thierry Andre - Sorbonne University and Saint-Antoine Hospital, Paris, Fran...
5 Jun 2020
Highlights from ASCO 2020
Dr Bishal Gyawali - Queen's University, Kingston, Canada
5 Jun 2020
PARP inhibitors in prostate cancer: Guidelines, who to test and the patient path...
Dr Neal Shore and Dr Elena Castro
5 Jun 2020
New emerging treatment options and targeted therapies for bladder cancer
Dr Arlene Siefker-Radtke and Dr Yohann Loriot
4 Jun 2020
Timing of response to venetoclax combination treatment in older patients with ac...
Dr Brian Jonas - University of California Davis Comprehensive Cancer Center, Sac...
3 Jun 2020
CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first...
Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, ...
2 Jun 2020
ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer
Prof Benjamin Besse and Dr Alex Spira
2 Jun 2020
Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple mye...
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
1 Jun 2020
KRd vs VRd for initial therapy of newly diagnosed multiple myeloma
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
1 Jun 2020
Teclistamab for patients with heavily pretreated relapsed or refractory multiple...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
1 Jun 2020
E2108: Systemic therapy plus early local therapy versus systemic therapy alone i...
Dr Seema Ahsan Khan - Northwestern Memorial Hospital, Chicago, USA
31 May 2020
KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy f...
Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA
31 May 2020
Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and ...
Dr Dimpy Shah - Mays Cancer Center at UT Health San Antonio MD Anderson, San Ant...
31 May 2020
Cumulative incidence of financial hardship in metastatic colorectal cancer patie...
Dr Veena Shankaran - Fred Hutchinson Cancer Research Center, Seattle, USA
30 May 2020
Denosumab in multiple myeloma patients with renal insufficiency
Dr Elizabeth O'Donnell - Massachusetts General Hospital, Boston, USA
30 May 2020
Association of BRCA alterations with response to PARP inhibitors in metastatic c...
Dr Emmanuel Antonarakis - John Hopkins Sidney Kimmel Comprehensive Cancer Center...
30 May 2020
LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progres...
Prof Michael Hofman - Peter MacCallum Cancer Centre, Melbourne, Australia
30 May 2020
The paediatric precision oncology study INFORM: Clinical outcome and benefit for...
Dr Cornelis van Tilburg - Hopp Children's Cancer Center Heidelberg, Heidelberg, ...
30 May 2020
Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chem...
Prof Thomas Powles - Barts Cancer Institute, London, UK
29 May 2020
Brigatinib for NSCLC, latest research and overcoming complications
Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA
29 May 2020
Sym015 shows superior specificity compared to TKIs for NSCLC
Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA
29 May 2020
CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell th...
Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA
29 May 2020
Update from KAITLIN for high-risk HER2-positive early breast cancer
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
29 May 2020
Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associate...
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
29 May 2020
Better genetic diagnostics in Ugandan breast cancer patients
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
29 May 2020
ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer
Prof Roy Herbst - Yale Cancer Center, New Haven, USA
29 May 2020
Pembrolizumab plus chemotherapy for patients with metastatic triple-negative bre...
Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain
27 May 2020
More from
e
cancer